MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, and RVMDShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Qiagen Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Qiagen (NYSE:QGEN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations. Which has more risk & volatility, QGEN or MOR? Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Which has higher earnings and valuation, QGEN or MOR? Qiagen has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.18$83.59M$1.6927.26MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media favor QGEN or MOR? In the previous week, Qiagen had 14 more articles in the media than MorphoSys. MarketBeat recorded 14 mentions for Qiagen and 0 mentions for MorphoSys. Qiagen's average media sentiment score of 1.33 beat MorphoSys' score of 0.00 indicating that Qiagen is being referred to more favorably in the media. Company Overall Sentiment Qiagen Positive MorphoSys Neutral Is QGEN or MOR more profitable? Qiagen has a net margin of 18.30% compared to MorphoSys' net margin of -226.79%. Qiagen's return on equity of 14.77% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% MorphoSys -226.79%-694.31%-22.55% Do institutionals & insiders hold more shares of QGEN or MOR? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate QGEN or MOR? Qiagen currently has a consensus price target of $49.69, indicating a potential upside of 7.84%. Given Qiagen's stronger consensus rating and higher possible upside, equities analysts clearly believe Qiagen is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryQiagen beats MorphoSys on 14 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$851.80M$5.76B$9.84BDividend YieldN/A4.84%3.95%4.02%P/E Ratio-5.451.1531.3126.60Price / Sales11.9926.88461.30121.37Price / CashN/A19.5637.7659.36Price / Book54.176.7310.026.67Net Income-$205.35M-$4.20M$3.27B$265.59M7 Day PerformanceN/A15.29%3.17%3.42%1 Month PerformanceN/A16.58%4.34%1.09%1 Year PerformanceN/A33.25%44.11%23.85% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730QGENQiagen4.0055 of 5 stars$48.66-1.4%$49.69+2.1%+7.3%$10.97B$1.98B28.755,765MRNAModerna4.4891 of 5 stars$28.09+0.2%$43.59+55.2%-68.2%$10.90B$3.24B-3.735,800BBIOBridgeBio Pharma4.2208 of 5 stars$49.02-4.5%$61.35+25.2%+98.5%$9.81B$221.90M-11.99400VRNAVerona Pharma PLC American Depositary Share2.4848 of 5 stars$105.79+0.5%$109.00+3.0%+289.3%$8.96B$42.28M-106.8630Positive NewsELANElanco Animal Health2.8656 of 5 stars$17.72-1.4%$17.33-2.2%+21.6%$8.92B$4.44B20.609,000BPMCBlueprint Medicines0.4133 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640News CoverageROIVRoivant Sciences3.1844 of 5 stars$11.81-0.3%$16.50+39.7%+1.2%$8.06B$29.05M-16.87860GRFSGrifols3.588 of 5 stars$10.58-1.3%$10.30-2.6%+11.9%$7.37B$7.45B9.0423,822Positive NewsLEGNLegend Biotech3.8863 of 5 stars$37.45-0.1%$72.38+93.3%-39.1%$6.89B$627.24M-42.562,609News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.318 of 5 stars$36.45+0.4%$69.54+90.8%-12.7%$6.79B$11.58M-8.10250News CoveragePositive News Related Companies and Tools Related Companies QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors ELAN Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access